In vitro diagnostic system for early detection of diabetic kidney disease through urine analysis. Combines dry-reagent technology with multi-channel detection of key biomarkers including urine microalbumin, uromodulin, and creatinine. Enables both clinical laboratory quantitative analysis and point-...
Manufactured by
Anhui Huibang Biological Engineering Co., Ltd.
China
National high-tech enterprise established in 2013, specializing in precision medicine diagnostics. Product lines include diabetic nephropathy tests, maternal and child health diagnostics, cardiovascular disease markers, tumor markers, and monoclonal antibody raw materials. Holds over 40 national patents with total investment of 450 million RMB.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Nova Biomedical Corporation
United States · 1 relevant product
Bio Preventive Medicine Co. Ltd.
Taiwan · 6 relevant products
Mediwhale Inc.
South Korea · 1 relevant product
51 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →11 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 78 closest product alternatives
Nova Biomedical Corporation · United States
Point-of-care diagnostic instrument for detecting kidney disease markers outside traditional hospital settings. Enables rapid assessment of renal function through blood or urine analysis, supporting early disease identification and patient monitoring in clinical and remote care environments.
Bio Preventive Medicine Co. Ltd. · Taiwan
An in vitro diagnostic test that predicts the risk of rapid renal function decline in diabetic kidney disease patients. This urine-based biomarker test provides early risk assessment before symptomatic deterioration occurs, enabling timely clinical intervention.
Bio Preventive Medicine Co. Ltd. · Taiwan
A comprehensive biomarker diagnostic panel for assessing the progression risk of diabetic kidney disease and predicting end-stage kidney disease development. The test utilizes novel biomarker technologies to stratify patient risk and guide personalized treatment decisions.
75 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products